Phase 1 study of balinatunfib, an oral inhibitor of TNFR1 signal in mild-to-moderate psoriasis.

Nassr N, Chow OA, Nguyen MA, Perrin L, Schumacher F, Wagner FD, Dreis C, Lahmar A, Kohlmann M, Wiekowski M, Matos TR

DOI: 10.1111/jdv.70262
Published: 2026 Jun
Container: Journal of the European Academy of Dermatology and Venereology : JEADV
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/jdv.70262,
  title = {Phase 1 study of balinatunfib, an oral inhibitor of TNFR1 signal in mild-to-moderate psoriasis.},
  author = {Nassr N and Chow OA and Nguyen MA and Perrin L and Schumacher F and Wagner FD and Dreis C and Lahmar A and Kohlmann M and Wiekowski M and Matos TR},
  year = {2026},
  journal = {Journal of the European Academy of Dermatology and Venereology : JEADV},
  doi = {10.1111/jdv.70262},
  url = {https://doi.org/10.1111/jdv.70262}
}

RIS

TY  - JOUR
TI  - Phase 1 study of balinatunfib, an oral inhibitor of TNFR1 signal in mild-to-moderate psoriasis.
AU  - Nassr N
AU  - Chow OA
AU  - Nguyen MA
AU  - Perrin L
AU  - Schumacher F
AU  - Wagner FD
AU  - Dreis C
AU  - Lahmar A
AU  - Kohlmann M
AU  - Wiekowski M
AU  - Matos TR
PY  - 2026
JO  - Journal of the European Academy of Dermatology and Venereology : JEADV
DO  - 10.1111/jdv.70262
UR  - https://doi.org/10.1111/jdv.70262
ER  -

APA

N, N., OA, C., MA, N., L, P., F, S., FD, W., C, D., A, L., M, K., M, W., & TR, M. (2026). Phase 1 study of balinatunfib, an oral inhibitor of TNFR1 signal in mild-to-moderate psoriasis.. Journal of the European Academy of Dermatology and Venereology : JEADV. https://doi.org/10.1111/jdv.70262

Source records

pubmed · retrieved 2026-09-27T01:15:51.542Z